계명대학교 의학도서관 Repository

Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C: A Korean Multi-Center Retrospective Study

Metadata Downloads
Author(s)
Soon Sun KimSun Hyuk HwangHyo Jung ChoDo Young KimHye Won LeeSu Jong YuYoung Youn ChoJeong Won JangByoung Kuk JangChang Wook KimHee Yeon KimHana ParkSo Young YoonGil Ho LeeSung Won ChoJae Youn Cheong
Keimyung Author(s)
Jang, Byoung Kuk
Department
Dept. of Internal Medicine (내과학)
Journal Title
대한간학회 춘·추계 학술대회
Issued Date
2018
Volume
2018
Issue
1
Keyword
CarcinomaHepatocellularHepatitis CChronicDirect-acting antiviral agentNeoplasm recurrenceRisk factors
Abstract
Aims: The risk factor of hepatocellular carcinoma (HCC) recurrence
following direct-acting antiviral (DAA) therapy remains
unclear. The aims: of this study were to estimate the rate of
HCC recurrence following DAA therapy in Korean patients with
chronic hepatitis C (CHC), and to evaluate the risk factors for
HCC recurrence after DAA therapy.
Methods: A total of 103 participants with CHC who obtained
complete response after HCC treatment were treated with
DAA between August 2015 and December 2016 and were followed
up until January 2018. HCC treatments were classified
as potentially curative included liver resection, radiofrequency
ablation, percutaneous ethanol injection, cryoablation and liver
transplantation.
Results: Among 103 patients, 82 patients had cirrhosis (79.2%)
and 98 patients had Child-Pugh class A (95.1%). HCC stage of
the patients was 49.6%, 38.9%, 9.7%, and 2.0% at stage I, II,
III, and IV, respectively, according to modified UICC classification.
Total duration of HCC treatment was median 2.3 (range, 0.03–
143.0) months, and interval from last HCC treatment to start
of DAA therapy was median 12.6 (range, 1.5–28.6) months.
During the median 15.7 (range, 4.3–29.9) months follow-up,
38 patients (36.9%) experienced tumor recurrence. The median
time to recurrence was 22.8 months. The univariate analyses
showed that lower platelet count, non-curative HCC treatment,
shorter interval from HCC treatment to DAA therapy and longer
total HCC treatment duration could be the risk factors for HCC
recurrence. In multivariate analysis, shorter interval from HCC
treatment to DAA therapy (<12 months) and longer total HCC
treatment duration (≥18 months) were found to be the independent
risk factors for HCC recurrence (hazard ratio [HR], 2.76;
95% confidence interval [CI], 1.21–6.30; P=0.016 and HR, 1.96;
95% CI, 1.00–3.83; P=0.049, respectively).
Conclusions: In CHC patients with HCC, DAA therapy should
be cautiously performed after sufficient interval without recurrence
after complete treatment response.
Keimyung Author(s)(Kor)
장병국
Publisher
School of Medicine (의과대학)
Citation
Soon Sun Kim et al. (2018). Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C: A Korean Multi-Center Retrospective Study. 대한간학회 춘·추계 학술대회, 2018(1), 74–75.
Type
Article
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/41272
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.